Gil M. Labrucherie Buys 10,500 Shares of Septerna, Inc. (NASDAQ:SEPN) Stock

Septerna, Inc. (NASDAQ:SEPN) CFO Gil M. Labrucherie bought 10,500 shares of the business’s stock in a transaction on Wednesday, February 19th. The stock was purchased at an average price of $5.51 per share, for a total transaction of $57,855.00. Following the completion of the acquisition, the chief financial officer now owns 10,500 shares of the company’s stock, valued at approximately $57,855. This trade represents a ∞ increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink.

Septerna Trading Down 1.5 %

Shares of NASDAQ:SEPN opened at $5.80 on Monday. Septerna, Inc. has a 12 month low of $4.17 and a 12 month high of $28.99. The stock’s fifty day moving average is $17.78.

Wall Street Analysts Forecast Growth

SEPN has been the topic of several analyst reports. JPMorgan Chase & Co. assumed coverage on shares of Septerna in a report on Tuesday, November 19th. They issued an “overweight” rating and a $38.00 target price on the stock. Cantor Fitzgerald restated an “overweight” rating and set a $50.00 price objective on shares of Septerna in a report on Tuesday, February 11th. TD Cowen assumed coverage on shares of Septerna in a report on Tuesday, November 19th. They set a “buy” rating on the stock. Finally, Wells Fargo & Company lowered shares of Septerna from an “overweight” rating to an “equal weight” rating and dropped their price objective for the stock from $43.00 to $14.00 in a report on Tuesday, February 18th.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in SEPN. RA Capital Management L.P. bought a new position in Septerna in the fourth quarter valued at $160,205,000. TRV GP V LLC bought a new position in Septerna in the fourth quarter valued at $142,337,000. TRV GP VI LLC bought a new position in Septerna in the fourth quarter valued at $72,191,000. Samsara BioCapital LLC bought a new position in Septerna in the fourth quarter valued at $63,399,000. Finally, Driehaus Capital Management LLC bought a new position in Septerna in the fourth quarter valued at $59,301,000.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.